Emerging Developments into a Disease Associated with an Ageing Population

LONDON, ENGLAND, UNITED KINGDOM, February 1, 2016 /EINPresswire.com/ -- SMi is thrilled to introduce the inaugural Alzheimer's conference, taking place on 10th and 11th May 2016 in Central London, UK. The agenda features a mix of case study led presentations, panel debates, interactive workshops and keynote addresses that have been tailored for an audience of specialists in neuroscience, drug discovery and pathology, providing a focal point for the industry to discuss the latest therapeutic developments.

As more and more people live longer and the population ages, Alzheimer's has been identified as one of the biggest health problems in the 21st century. In the UK alone, a new report by the HSCIC has indicated that the number of patients being prescribed with drugs to treat Alzheimer’s has risen six-fold in the last 10 years. A 5 year strategy to fight dementia unveiled by the UK Government last year, reflects greater efforts to tackle the disease in the UK.

Alzheimer’s 2016 will hone in on early intervention strategies as well as solutions to on-going drug development challenges. It will strengthen knowledge in key topics such as; tau aggression; risk profiling; investment options; MRI imaging and biomarker evaluation, whilst looking at the practicalities of meaningful data from trials and keeping attendees at the forefront of clinical breakthroughs to adapt to the growing need for new treatments.

Understanding behavioral and psychiatric symptoms will be a major focus, as will hearing from a selection of pharmaceutical companies currently modelling disease progression. This will include case studies from Eli Lilly, Janssen Research & Development, GSK and Merck. An update on funding opportunities and academic drug discovery from Alzheimer’s Research UK, will be just one of the event highlights for 2016.

Key Speakers Include:

• Giulio Maria Pasinetti, Saunders Family Chair and Professor of Neurology, Icahn School of Medicine at Mount Sinai
• Luc Ver Donck, Scientific Director, Janssen Research & Development
• Steve Hood, Director, Biotransformation & Drug Disposition, GSK
• Matthew Kennedy, Director, Early Discovery Neuroscience, Merck
• Serge Van der Geyten, Director, Neuroscience External Affairs, Janssen Research & Development
• Michael J O’Neill, Head of Molecular Pathology Group, Eli Lilly
• Claude M Wischik, Executive Chairman, TauRx Therapeutics
• Simon Ridley, Director of Research, Alzheimer’s Research UK

For those who are interested in attending, there is currently a £400 early bird saving available online which expires on 29th February. A details agenda and full speaker line-up is available online at: www.alzheimers-conference.com

Alzheimer's 2016
10-11 May
Holiday Inn Kensington Forum, London UK

--- END ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Teri Arri
SMi Group
+442078276000
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.